

DISCOVERY AND PHASING OF A NOVEL NULL ALLELE IN A *FY*A/FY*B* INDIVIDUAL WITH NANOPORE SEQUENCING

M Gueuning¹, E Gourri^{1,2}, GA Thun¹, N Trost², Y Merki², K Neuenschwander², S Sigurdardottir², C Engström³, BM Frey^{1,2,3}, M Mattle-Greminger¹, S Meyer²

¹ Department of Research and Development, ² Department of Molecular Diagnostics and Cytometry, ³ Department of Immunohematology, Blood Transfusion Service Zurich, Schlieren, Switzerland



www.blutspendezurich.ch

Sequencing new blood group alleles as complete gene haplotypes could become the emerging standard



Background

The Duffy (Fy) blood group is encoded by *ACKR1*. The *FY*A/FY*B* alleles are defined by the SNV c.125G>A. We resolved a rare discrepant case between serology and genotyping using long-read Nanopore sequencing.

Methods



- > 40'000 donors genotyped with MALDI-TOF MS for 3 SNVs on *ACKR1*
- Fy phenotyping for ~ 13'200 donors → 1 discrepancy investigated:
- Nanopore sequencing
- Confirmation with Sanger sequencing

Results

- Heterozygous *FY*A/FY*B* individual expressing Fy(a-b+) phenotype
- Nanopore sequencing revealed a 1bp deletion located on the *FY*A* allelic background (c.655delG, V219Sfs*13)
- This frameshift mutation is yet undescribed

Conclusion

In this proof-of-principle study, we showed that Nanopore sequencing, which, unlike Sanger sequencing, allows haplotype generation along the whole gene, proved well-suited to resolve a discrepancy between Duffy blood group genotype and phenotype.



Direct phasing of novel variant to *FY*A* allelic background by Nanopore sequencing

